References
- Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
- Gridelli C , Peters S , Sgambato A , Casaluce F , Adjei AA , Ciardiello F . ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat. Rev. 40(2), 300–306 (2014).
- Lee JK , Park HS , Kim DW et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced non-small-cell lung cancer. Cancer 118(14), 3579–3586 (2012).
- Peng L , Zhu L , Sun Y et al. Targeting ALK rearrangements in NSCLC: current state of the art. Front. Oncol. 12, 863461 (2022).
- Horn L , Infante JR , Reckamp KL et al. Ensartinib (X-396) in ALK-positive non-small-cell lung cancer: results from a first-in-human Phase I/II, multicenter study. Clin Cancer Res. 24(12), 2771–2779 (2018).
- Fang W , Ma Y , Huang J et al. Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small-cell lung cancer: a Phase I, dose-escalation study. J. Clin. Oncol. 36(Suppl. 15), e21122 (2018).
- Ma Y , Pan H , Liu Y et al. Ensartinib in advanced ALK-positive non-small-cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. J Thorac Dis. 14(12), 4751–4762 (2022).
- Yang Y , Zhou J , Zhou J et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir Med. 8(1), 45–53 (2020).
- Horn L , Wang Z , Wu G et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized clinical trial. JAMA Oncol. 7(11), 1617–1625 (2021).
- Soria JC , Tan DSW , Chiari R et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389(10072), 917–929 (2017).
- Camidge DR , Kim HR , Ahn MJ et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 16(12), 2091–2108 (2021).
- Crinò L , Ahn MJ , De Marinis F et al. Multicenter Phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J. Clin. Oncol. 34(24), 2866–2873 (2016).
- Kim DW , Tiseo M , Ahn MJ et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter Phase II trial. J. Clin. Oncol. 35(22), 2490–2498 (2017).
- Peters S , Camidge DR , Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377(9), 829–838 (2017).
- Camidge DR , Kim HR , Ahn MJ et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naïve ALK-positive non-small-cell lung cancer: second interim analysis of the Phase III ALTA-1L trial. J. Clin. Oncol. 38(31), 3592–3603 (2022).